Join

Compare · DGX vs LH

DGX vs LH

Side-by-side comparison of Quest Diagnostics Incorporated (DGX) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DGX and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
  • DGX is the larger of the two at $21.50B, about the same size as LH ($21.11B).
  • DGX has been more active in the news (15 items in the past 4 weeks vs 9 for LH).
  • Both have 25 recent analyst ratings on file.
MetricDGXLH
Company
Quest Diagnostics Incorporated
Labcorp Holdings Inc.
Price
-
-
Market cap
$21.50B
$21.11B
1M return
-
-
1Y return
-
-
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NYSE
IPO
News (4w)
15
9
Recent ratings
25
25
DGX

Quest Diagnostics Incorporated

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

LH

Labcorp Holdings Inc.

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

Latest DGX

Latest LH